https://radforsk.no/wp-content/uploads/2016/11/Photocure.jpg4301500radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2017-02-15 15:01:132019-01-17 08:51:02Photcure with full year report
Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis. Large privately owned investment companies joining the Company as new investors include Geveran Trading Co. Ltd., Canica AS, CGS Holding AS, Helene […]
Our portfolio company PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”. The main goal of the project is to document in a proof-of-principle clinical study in cancer patients that PCI Biotech’s photochemical internalization (PCI) technology can be used […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2017-01-27 14:06:502019-01-17 08:51:02PCI Biotech awarded NOK 13.8 million from The Research Council of Norway
The grant will be used to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2017-01-17 10:13:232019-01-17 08:51:02Oncoimmunity granted NOK 300,000 from Innovation Norway
https://radforsk.no/wp-content/uploads/2015/06/ProjectPort.jpg300500radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2017-01-09 19:58:362019-01-17 08:51:02PCI Biotech and Ultimovacs awarded NOK 500,000 from Innovation Norway
Photcure with full year report
/in Portfolio Companies /by radforskRadforsk porfolio company Photocure reported a revenue growth of 10 % to NOK 38.1 million in the fourth quarter of 2016.
Oncoinvent closes $ 25 Million Private Placement
/in Portfolio Companies /by radforskOur portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis. Large privately owned investment companies joining the Company as new investors include Geveran Trading Co. Ltd., Canica AS, CGS Holding AS, Helene […]
PCI Biotech awarded NOK 13.8 million from The Research Council of Norway
/in Portfolio Companies /by radforskOur portfolio company PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”. The main goal of the project is to document in a proof-of-principle clinical study in cancer patients that PCI Biotech’s photochemical internalization (PCI) technology can be used […]
Oncoimmunity granted NOK 300,000 from Innovation Norway
/in Radforsk /by radforskThe grant will be used to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.
PCI Biotech and Ultimovacs awarded NOK 500,000 from Innovation Norway
/in Portfolio Companies /by radforskThe grant will be used to further development of the existing preclinical research collaboration of the two companies.
CEO Jónas Einarsson in E24
/in Radforsk /by radforsk*From the laboratory to rocket on the stock exchange – he turns medicine to gold.*
Vaccibody raised MNOK 220
/in Portfolio Companies /by radforskThe Private Placement was significantly oversubscribed by both existing shareholders and new investors.
PCI Biotech: Successful Investigational New Drug application
/in Portfolio Companies /by Elisabeth AndersenPCI Biotech has received clearance by the United States Food and Drug Administration (FDA) to include patients in the US.
Nordic Naonvector raised 497 MNOK
/in Portfolio Companies /by Elisabeth AndersenThe Private Placement was oversubscribed and attracted strong interest from both existing shareholders and new institutional investors.